


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-93. (Cancelled)

94. (Currently Amended) An ANT ligand having the following structure:



and stereoisomers and pharmaceutically acceptable salts thereof,

wherein

R₁ is ~~hydroxyl~~, halogen, -OC(=O)R₄ or -NHR₄;

R₂ is hydrogen or -C(=O)R₅;

R₃ is -CH₃ or =CH₂;

R₄ is ~~-X-aryl~~, ~~-X-substituted-aryl~~, -X-arylalkyl, -X-substituted
arylalkyl, X-heteroaryl, or -X-heteroarylalkyl, wherein X is an optional amido or alkylamido
linker moiety; and

R₅ is alkyl.

95. (Cancelled)

96. (Currently Amended) The ANT ligand of claim 94 wherein R₁ is -OC(=O)R₄.

97. (Original) The ANT ligand of claim 94 wherein R₁ is -NHR₄.

98. (Original) The ANT ligand of claim 94 wherein R₂ is hydrogen.

99. (Original) The ANT ligand of claim 94 wherein R₂ is -C(=O)R₅.

100. (Original) The ANT ligand of claim 94 wherein R₃ is -CH₃.

101. (Original) The ANT ligand of claim 94 wherein R₃ is =CH₂.

102. (Currently Amended) The ANT ligand of claim 94 wherein R₄ is ~~-X-aryl,~~
~~-X-substituted aryl,~~ -X-arylalkyl or -X-substituted arylalkyl.

103-107. (Cancelled)

108. (Original) A pharmaceutical composition comprising an ANT ligand of claim 94.

109-112. (Cancelled)